Get the Stockscreener App
18.00
4.90%
0.84
Denali Therapeutics Inc stock is traded at $18.00, with a volume of 1.44M.
It is up +4.90% in the last 24 hours and up +6.13% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$17.16
Open:
$16.93
24h Volume:
1.44M
Relative Volume:
0.78
Market Cap:
$2.64B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-6.3158
EPS:
-2.85
Net Cash Flow:
$-402.10M
1W Performance:
+3.21%
1M Performance:
+6.13%
6M Performance:
+31.48%
1Y Performance:
-25.68%
1-Day Range:
$16.87
$18.23
1-Week Range:
$16.85
$18.23
52-Week Range:
$10.57
$26.18
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
18.00 | 2.52B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Transcript : Denali Therapeutics Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 12 - MarketScreener
How Denali Therapeutics Inc. stock trades during market volatility2025 Volatility Report & Reliable Trade Execution Plans - newser.com
How risky is Denali Therapeutics Inc. (4DN) stock compared to peers - newser.com
Denali Therapeutics announces board and leadership changes By Investing.com - Investing.com Nigeria
How strong dollar benefits Denali Therapeutics Inc. (4DN) stockJuly 2025 Trends & Community Consensus Picks - newser.com
Why Denali Therapeutics Inc. (4DN) stock benefits from AI revolution2025 Stock Rankings & Real-Time Volume Triggers - newser.com
Is Denali Therapeutics Inc. (4DN) stock at risk of policy regulationTrade Risk Report & AI Based Buy and Sell Signals - newser.com
Is Denali Therapeutics Inc. stock a defensive play in 2025Market Risk Summary & Risk Managed Investment Strategies - newser.com
Will Denali Therapeutics Inc. stock gain from lower inflationSwing Trade & High Conviction Investment Ideas - newser.com
Is Denali Therapeutics Inc. stock a contrarian buy2025 Trade Ideas & Accurate Buy Signal Notifications - newser.com
Is Denali Therapeutics Inc. (4DN) stock positioned for digital growth eraQuarterly Investment Review & Capital Efficient Trade Techniques - newser.com
Published on: 2025-11-19 17:06:18 - newser.com
Can Denali Therapeutics Inc. (4DN) stock resist broad market declinesTrade Exit Summary & Weekly Stock Breakout Alerts - newser.com
Applying sector rotation models to Denali Therapeutics Inc.Quarterly Risk Review & Weekly Return Optimization Alerts - newser.com
How Denali Therapeutics Inc. (4DN) stock performs in easing cyclesJuly 2025 Institutional & Momentum Based Trading Ideas - newser.com
Denali Therapeutics Inc. (4DN.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Denali Therapeutics Inc. stock supported by strong cash flowsEarnings Miss & Daily Volume Surge Trade Alerts - newser.com
Will Denali Therapeutics Inc. (4DN) stock outperform small cap peers2025 Price Momentum & Reliable Trade Execution Plans - newser.com
Why Denali Therapeutics Inc. stock remains on watchlists2025 Top Decliners & Technical Buy Zone Confirmations - newser.com
Will Denali Therapeutics Inc. (4DN) stock beat international competitionJuly 2025 Macro Moves & Reliable Volume Spike Trade Alerts - newser.com
Why Denali Therapeutics Inc. stock is favored by pension fundsTrade Analysis Report & Verified Swing Trading Watchlist - newser.com
Will Denali Therapeutics Inc. stock outperform Nasdaq indexIndex Update & Weekly High Return Stock Forecasts - newser.com
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):